{
    "title": "115_hr5590",
    "content": "The \"Opioid Addiction Action Plan Act\" is a legislation aimed at preventing opioid addictions and improving access to medication-assisted treatment under Medicare and Medicaid. The Secretary of Health and Human Services, in collaboration with the Pain Management Best Practices Inter-Agency Task Force, must develop an action plan by January 1, 2019, to address obstacles in responding to the opioid crisis. This plan will include recommendations for changes to Medicare and Medicaid programs to enhance coverage and payment for medication-assisted treatment. The curr_chunk discusses recommendations for payment and service delivery models to be tested by the Center for Medicare and Medicaid Innovation, specifically focusing on medication-assisted treatment for opioid addiction and other pain management therapies. The goal is to make separate payments for these therapies if medically appropriate to encourage their development and adoption. The curr_chunk focuses on recommendations for data collection and policies under the Medicare and Medicaid programs to prevent opioid addiction, expand access to treatment in rural communities, and cover appropriate therapies. The curr_chunk discusses recommendations for expanding access to medication-assisted treatment and non-opioid based therapies for pain management in underserved communities. It also mentions stakeholder meetings to be conducted by the Secretary within 3 months of the Act's enactment. The Secretary will convene a stakeholder meeting to gather public feedback on action plan recommendations related to the opioid crisis. Participants will include representatives from various sectors. Additionally, a request for information will be issued to seek public input on how Medicare & Medicaid Services can address the crisis. The Secretary will report to Congress by June 1, 2019, with recommendations from the action plan, planned next steps, and an evaluation of drug prices for opioid overdoses. Medication-assisted treatment includes opioid programs, therapy, and medications for substance abuse disorder. Passed the House of Representatives on June 19, 2018. Attest: KAREN L. HAAS, Clerk."
}